The scholarly study motivated that the rate of use was 4.4 % among adolescents who got at least among the aforementioned respiratory conditions, like the rate among adolescents overall . The usage of inhalants can significantly impair the proper functioning of the respiratory system in usually healthy individuals resulting in unconsciousness, coma or death – so it may pose an even greater risk to people that have serious underlying respiratory circumstances. Under any situations, inhalant use, or ‘huffing’ can cause severe permanent injury or death even after just one use.No safety problems were observed, in virtually any of the dose organizations. Related StoriesAlport syndrome: an interview with Dr Paul Grint, CMO, RegulusDiabetic retinopathy therapy improvements: an interview with Richard Kirk, CEO of PolyphotonixElectronic cigarettes and smoking cigarettes cessation: an interview with Professor Peter Hajek The trial also established recAP's pharmacokinetic properties. These include dose exposures up to and above the mark therapeutic range as established in AM-Pharma's earlier positive Phase II clinical trial outcomes with bovine Alkaline Phosphatase , in the treating sufferers with Acute Kidney Injury . ‘Our wealth of understanding around Alkaline Phosphatase, obtained from our earlier Phase II programmes with bovine AP, meant that at the start of this scientific trial we anticipated that recAP would be secure and well tolerated,’ stated Erik van den Berg, CEO of AM-Pharma.